2016 Annual Conference
This educational initiative, derived from the AONN+ Seventh Annual Navigation & Survivorship Meeting, is designed to meet the educational needs of hematology/oncology nurse navigators and registered nurses; other healthcare professionals, such as patient navigators and social workers who have a focus on cancer and survivorship, are encouraged to participate.
Attendees were up bright and early on Saturday morning, ready to enjoy yet another day packed with informational sessions and activities. The day began with a product theater sponsored by Genomic Health, and presented by Mary Van Cleave, BSN, RN, OCN. Her presentation, titled Harnessing the Power of Genomics, began with reminding attendees about the differences between genomics and genetics.
The morning began with a breakfast N.E.X.T. Day session sponsored by Bristol-Myers Squibb. Peg Esper, DNP, ANP-BC, AOCN, discussed Opdivo (nivolumab) therapy, which is a fully human monoclonal antibody indicated for previously treated metastatic non–small-cell lung cancer. She reviewed the CheckMate 057 study, which looked at standard-of-care therapy, docetaxel, and Opdivo.
More than 900 nurse and patient navigators converged on the Las Vegas Aria today to kick off AONN+’s Seventh Annual Navigation & Survivorship Conference! For participants, the day began with the long-awaited nurse navigation and patient navigation certification exams. These are the industry’s first certifications specifically for navigators, and AONN+ is honored to be setting the standard in this area.
Results 1 - 5 of 5